ENTO Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Entero Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.07 |
52 Week High | US$30.40 |
52 Week Low | US$0.95 |
Beta | 1.35 |
11 Month Change | -56.19% |
3 Month Change | -71.69% |
1 Year Change | -96.21% |
33 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
First Wave BioPharma announces pricing of $6.0 million public offering
Oct 07First Wave BioPharma extends selloff after announcing strategic shift
Sep 19First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase
Sep 07First Wave BioPharma announces 1-for-30 reverse stock split
Aug 25First Wave BioPharma to raise capital in convertible preferred stocks offering
Jul 15First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment
Oct 19AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study
Jun 07AzurRx BioPharma: An Assessment
May 02AzurRx Officially A COVID-19 Play - The Right Dose For Your Portfolio
Jan 31AzurRx BioPharma, First Wave Bio in niclosamide licensing pact for gastrointestinal infections
Jan 04AzurRx up 9% on advancement of mid-stage study of MS1819 in CF patients
Nov 30Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?
Nov 19Shareholder Returns
ENTO | US Biotechs | US Market | |
---|---|---|---|
7D | -13.0% | -1.4% | 1.8% |
1Y | -96.2% | 10.5% | 24.2% |
Return vs Industry: ENTO underperformed the US Biotechs industry which returned 10.4% over the past year.
Return vs Market: ENTO underperformed the US Market which returned 24% over the past year.
Price Volatility
ENTO volatility | |
---|---|
ENTO Average Weekly Movement | 14.0% |
Biotechs Industry Average Movement | 10.2% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ENTO's share price has been volatile over the past 3 months.
Volatility Over Time: ENTO's weekly volatility has decreased from 20% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 9 | James Sapirstein | www.enterothera.com |
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
Entero Therapeutics, Inc. Fundamentals Summary
ENTO fundamental statistics | |
---|---|
Market cap | US$2.65m |
Earnings (TTM) | -US$6.44m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs ENTO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ENTO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$6.44m |
Earnings | -US$6.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.60 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 8.7% |
How did ENTO perform over the long term?
See historical performance and comparison